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Globally, lower respiratory tract infections (LRTIs), including 
community-acquired pneumonia (CAP), cause considerable of 
morbidity and mortality in adults, especially in the elderly. In 
addition to age, underlying medical conditions are associated 
with an increased risk of CAP. From an aetiological point of view, 
Streptococcus pneumoniae is the leading cause of adult CAP 
throughout the world. Two types of vaccine are available for the 
prevention of pneumococcal diseases: the pneumococcal polysac-
charide vaccine (PPV23) and the pneumococcal conjugate vac-
cine (PCV7, PCV10 and PCV13). An accurate understanding of 
the LRTIs burden and the types of subjects at risk of CAP, allow to 
find an appropriately targeted immunization strategy and provide 
baseline data to evaluate pneumococcal vaccine effectiveness. 
Given the high variability in available estimates of LRTIs bur-
den and associated risk factors, the objective of the study was to 
discuss the methodological criticism in its evaluation, in the light 
of the gradual introduction of PCV13 immunization strategy tar-
geted to elderly and risk groups in middle-high income countries.
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Summary
Introduction
Globally, LRTIs, including CAP, are a major cause of 
morbidity and mortality in adults in developed coun-
tries, leading to high hospitalizations rates, especially in 
the elderly [1-4].
According to recent estimates, LRTIs are the fourth 
most common cause of death, exceeded only by ischae-
mic heart disease, strokes and chronic obstructive pul-
monary disease (COPD), and 1.9 million adults aged 
≥15 years die from LRTIs every year worldwide. The 
2010 Global Burden of Disease Study reported also 
that LRTIs, are the second most frequent reason for 
years of life lost [5].
Among Europe, CAP is the leading cause of death due to 
infection [4], with almost 90% of deaths due to pneumo-
nia occurring in subjects > 65 years-old [6]. Pneumonia 
has also a substantial burden on healthcare resources and 
society, with associated annual costs in Europe estimat-
ed at approximately €10 billion, mostly due to hospitali-
zation and lost working days [7].
Studies have shown that the risks of CAP and CAP-re-
lated deaths increase with age and are highest among the 
elderly [2, 3], indicating that the burden of pneumonia 
is growing in this era of global population aging [8-11]. 
The “oldest old” (≥ 85 years) are at particularly high risk 
of infections, due to comorbidities and waning immune 
function [12]. Moreover, in these subjects CAP can have 
serious consequences and aggravate underlying comor-
bidities [13].
In addition to age >65 years, other risk factors for CAP 
are recognized, such as chronic cardiovascular or res-
piratory diseases, cerebrovascular diseases, epilepsy, 
dementia, dysphagia, chronic liver or renal diseases, 
lifestyle factors (smoking, alcohol consumption, being 
underweight, regular contact with children and dental 
hygiene), and immunosuppressive conditions [14, 15].
From an aetiological point of view, Streptococcus pneu-
moniae is the leading cause of adult CAP throughout 
the world [3, 16, 17], and has been estimated to be the 
cause of 30-50% cases of CAP requiring hospitalization 
in adults in developed countries [18]. Nevertheless, in 
high-income countries it has been decreasing as a conse-
quence of the wide use of antibiotics and of the introduc-
tion of pneumococcal vaccines [19]. 
From the clinical and public health perspectives, esti-
mates of the overall health care burden and aetiological 
patterns of CAP are crucial for effective disease control 
programs [1, 2]; however, available estimates largely 
vary, so that its true burden remains unclear.
The objective of the present study is to discuss the meth-
odological criticism in the evaluation of the burden of 
LRTIs, including pneumonia, and of the pneumococcal 
vaccine effectiveness, in the light of the gradual intro-
duction of PCV13 immunization strategy targeted to el-
derly and risk groups in middle-high income countries.
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Knowledge gap for PCV introduction  
in adults: criticisms in the definition  
of the burden of pneumonia and lRTIs
Although LRTIs, including pneumonia, are common 
diseases, the real burden and their related risk factors 
remain unclear, even in high-income countries [20]. 
Available incidence estimates largely vary, making the 
comparison of LRTIs and CAP incidence obtained from 
different studies difficult (Fig. 1) [15].
Epidemiological studies conducted in the second half 
of 2000 among adults have reported hospitalization rate 
of about 1.1 and 2.8 per 1,000 year in the UK and in 
Germany, respectively [21, 22]. The overall incidence 
estimated in hospitalized adult patients for CAP who 
lived in two countries in Ohio, USA, was 2.6 per 1,000 
inhabitants year [23]. Furthermore, a study conducted in 
Denmark between 1993 and 2008 reported rate of hospi-
talization for pneumonia lower than 4 per 1,000 in adults 
aged >50 years [24].
Several factors explain the variation of available CAP 
estimates and they are deepen below.
First, the performance of surveillance system in terms 
of specificity and sensitivity in capturing LRTI cases is 
suboptimal. This limit could be overcome using a syn-
dromic surveillance system that combines high sensitiv-
ity in identifying suspected cases obtained by scanning 
the chief complaint field for the word strings assigned 
to the single syndrome and automatic review of ED ac-
ceptance data folders and high specificity as a result of 
critical revision of each reported case according to the 
operative case definition [15].
Second, the definition of pneumonia differs among 
studies [25]: some studies used chest X-ray findings to 
determine pneumonia [9, 11, 26], whereas others used 
clinically defined criteria or simply relied on reported 
cases at the sentinel sites [25, 27]. Additionally, the 
diagnosis of pneumonia is not standardized in clinical 
settings [20]. Furthermore some studies have reported 
incidences of CAP including both outpatients and hos-
pitalized patients [11, 29], while other studies evaluated 
hospitalized cases only [21, 30], introducing a selective 
bias towards severe patients. Lastly, mild cases must be 
overlooked in countries in which access to health care is 
limited, affecting the incidence estimates by the health 
care-seeking pattern [20].
Third, the heterogeneity of study design and difference 
in the underlying risk profile and age categorizations of 
the populations studied [12, 31-33] produce different es-
timates [20]. Furthermore, some studies of regional and 
socio-economic variations in LRTIs incidence have not 
age-stratified further after 65 years, but this group in-
clude very different subjects, both people working full-
time and those that require round-the clock care [12].
Last but not the least, available incidence estimates 
also vary from setting to setting, reflecting nation-
al differences in health systems and medical prac-
tice [3,  11, 12, 21, 28-30, 34-35].
The pneumococcal immunization 
strategies in adults
Currently, two type of vaccines are available to prevent 
pneumococcal-related disease in adults: a polysaccha-
ride vaccine and pneumococcal conjugate vaccines [36].
During 1970s the PPV-23 was introduced in high-
income countries for the prevention of pneumococcal 
Fig 1. differences in available LrTIs incidence estimates by age group [30, 75].
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diseases caused by the 23 serotypes (1, 2, 3, 4, 5, 6B, 
7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 
19A, 20, 22F, 23F, 33F) in adults and children aged ≥2 
years [37].
Furthermore, in many countries the PPV23 has been 
recommended for high-risk groups, including the el-
derly  [38, 39]. However, there is little evidence that it 
is effective in adults with chronic diseases and in the 
elderly [40,41].
Although available systematic reviews and meta-anal-
yses demonstrate that PPV23 confer protection against 
invasive pneumococcal disease (IPDs) [38, 41], its du-
ration is limited [42, 43], and its effectiveness against 
pneumococcal pneumonia is still controversial, particu-
larly for the elderly [40, 41].
The first pneumococcal conjugate vaccine (PCV7) was 
licensed in 2000 for protection against IPDs, including 
sepsis, meningitis, and non-invasive diseases, such as 
pneumonia and acute otitis media (AOM), caused by the 
seven serotypes contained in the vaccine (4, 6B, 9V, 14, 
18C, 19F and 23F) in infants and children aged from 2 
months to 5 years [44].
In 2009 PCV10 (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 
19F, and 23F) was approved for protection against IPDs, 
pneumonia and AOM in infants and children aged from 
6 weeks up to 5 years [45].
Today a PCV13 vaccine, including six additional sero-
types to PCV7 (1, 3, 5, 6A, 7F and 19A) is available for 
the prevention of IPDs and pneumococcal pneumonia in 
adults aged ≥18 years and the elderly, and for the pre-
vention of IPDs, pneumonia and AOM in infants and 
children aged between 6 weeks and 17 years [46].
Since 2006, the WHO has recommended that PCV be in-
cluded in all routine childhood immunization programs 
[47]. Of the European region member states, 49% had 
introduced PCV by 2012.
In countries with high immunization coverage the bene-
fits of childhood immunization have been observed over 
time also in unvaccinated children and adults, as a result 
of the “herd immunity” effect [48-51].
However, despite extensive childhood immunization 
plan, the burden in the elderly and high risk groups re-
mains high [15, 52]. 
Since the indication of PCV13 use has been extended 
to adults ≥ 50 years-old in 2011, its gradual inclusion 
in adults immunization plan has been observed in high-
income countries, in addition to childhood immuniza-
tion programs [53]. 
Nevertheless, pneumococcal immunization strategies 
vary with regards to age groups and risk groups to be 
immunized, the type vaccine (PPV and/or PCV) and the 
eligibility for reimbursement [15, 53].
Based on available epidemiological evidence, the best 
pneumococcal immunization strategy to reduce the bur-
den of LRTIs should be age- and risk-based. In fact, al-
though “at-risk strategy” has many disadvantages (i.e. 
difficult access to health services, involvement of dif-
ferent healthcare professionals, difficult to achieve high 
levels of vaccine uptake), it should be greatly imple-
mented and coupled by age-based strategy [15].
The majority of the Western European countries has imple-
mented this coupled strategy [53-54], however the number 
of identified risk groups and the age group eligible for vac-
cination varies in the different countries [36, 53]. 
PCV13 effectiveness estimation  
in prevention of lRTIs in elderly  
and risk groups
Today, the estimation of PCV13 effectiveness in pre-
vention of LRTIs in elderly and risk groups is of particu-
lar scientific interest due to its more recent introduction 
than PPV23, but it shows many methodological issues.
RCTs, such as the recently published CAPITA study 
[55], provide the most definitive data about the efficacy 
of PCV13 vaccine, but performing such trials is extreme-
ly difficult [56] and expensive and entails many ethical 
issues. In fact, pneumococcal vaccine is recommended 
in the elderly, those with chronic conditions and immu-
nosuppressed subjects, making placebo-controlled trials 
unethical in these groups [57]. Furthermore, pneumo-
coccal pneumonia is a relatively uncommon outcome, 
so RCTs of PCV13 must consider large populations to 
have adequate statistical power [56].
Existing observational methods for evaluating vaccine 
effectiveness, such as cohort and case-control studies, 
are cheaper and logistically easier, but they implies the 
risk of introduction of biases that may interfere with 
vaccine effectiveness estimates [56]. Routinely col-
lected administrative data don’t provide adequately 
accurate databases to estimate vaccine effectiveness. 
Furthermore many biases (some of which are difficult 
to detect) pose challenges in distinguishing vaccine-re-
lated effects from other potential confounders that may 
affect the same outcomes. They include differences in 
susceptibility to infection and differences in health care 
utilization in vaccinated and unvaccinated populations. 
In particular, vaccinated group usually include healthy 
subjects that have social interactions and then are ex-
posed to LRTIs. Conversely, they have a lower risk of 
developing complications and serious outcome, such as 
deaths, than unvaccinated subjects. As demonstrated in 
the study published by Weycker D et al. in 2010, the an-
nual incidence of non-bacteremic pneumococcal pneu-
monia requiring inpatient care is 17 and 10 folds higher 
in high risk subjects in 64-74 years and 75-84 years, re-
spectively [58]. Then, the evaluation of vaccinated and 
unvaccinated groups should take into account the differ-
ences in LRTIs outcomes.
Otherwise proxy indicators such as antibody response 
are not applicable, in particular to evaluate the effec-
tiveness against non-invasive diseases. Enzyme-linked 
immunosorbent assay (ELISA) can be used to measure 
antipneumococcal IgG antibodies [59], giving reproduc-
ible results. However, there is no consensus regarding 
the protective antibody levels in adults [56]. Further-
more, older adults develop antibodies characterized by 
reduced function [60] and ELISA cannot distinguish 
between functional and nonfunctional antibodies [61]. 
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Opsonophagocytic killing (OPK) activity [56] has been 
shown to correlate with immune protection in animal 
studies [60] and have also been shown to correlate with 
protection better than ELISA for AOM in children [62]. 
However, no available studies correlates OPK assay re-
sults with protection in adults [56].
Finally, it is hard to find the correct clinical and labo-
ratory endpoint to accurately estimate the incidence of 
pneumonia pneumococcal-related. The choice of clini-
cal pneumonia as an endpoint is therefore biased in 
favour of high sensitivity, at the expense of specific-
ity. Indeed, a large proportion of the cases that meet 
the case definitions for clinical pneumonia have a low 
positive predictive value and are, therefore, not pneu-
monia [63]. Conversely, radiologically-confirmed pneu-
monia is a relatively more specific measure of CAP and 
so evaluating vaccine efficacy on this outcome measure 
is a better indicator. Furthermore, the level of vaccine-
induced pneumococcal antibody in adults that corre-
lates with protection against clinical disease, including 
IPDs or pneumococcal pneumonia, has not been estab-
lished  [64]. Furthermore, classical microbiological as-
says, such as Gram-staining and culture from sputum 
and/or blood, understimates the burden of pneumococ-
cal pneumonia and the results are delayed. The isola-
tion of Streptococcus pneumoniae from blood allows a 
specific aetiological diagnosis but with a detection rate 
of 10%-20% [36]. Urinary antigen tests for Streptococ-
cus pneumoniae have been developed to overcome the 
limits of culture-based tests, and are characterized by 
high specificity and sensitivity in adults [65-68] and can 
help monitor changes in overall burden of pneumococ-
cal CAP [69] but they should be developed for a broader 
research use and a wider range of pneumococcal sero-
types, before their widespread use [64]; thus, document-
ing Streptococcus pneumoniae-specific impact is quite 
challenging [56].
Molecular methods represent another non-culture-based 
diagnostic approach that allows to rapidly and accurate-
ly quantify the bacterial load [36]. These methods are 
more sensitive than blood culture and may be a useful 
tool for the assessment of the severity of pneumococcal 
pneumonia [70].
Finally, molecular methods, in addition to conventional 
laboratory methods, are the best strategy to detect pneu-
mococcal pneumonia [71-74].
Conclusions
Available evidence show that the burden of LRTIs, in-
cluding pneumonia, in adults is relevant and strongly 
age- and risk factors-related [15]. Nevertheless the es-
timation of LRTIs and their prevalence in risk groups 
largely vary among published studies.
Considering the availability of effective vaccine in pre-
vention of pneumococcal pneumonia, i.e. PCV13, an ac-
curate understanding of the LRTIs burden and the types 
of subjects at risk of CAP, allow to find an appropriately 
targeted immunization strategy that optimize the vac-
cine effect and provide baseline data to evaluate pneu-
mococcal vaccine effectiveness [14, 15].
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